Citigroup Maintains Buy on Sana Biotechnology, Lowers Price Target to $11
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Samantha Semenkow maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.
Citigroup analyst Samantha Semenkow maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.
